Advertisement

Will This News Stop Ocugen Shares in Their Tracks?

Will This News Stop Ocugen Shares in Their Tracks?

The company signed a deal with Bharat Biotech to co-commercialize Bharat's near-to-market coronavirus vaccine candidate in the U.S. In recent days, the companies expanded the deal to include Canada as well. From the start of the year to a peak in February, Ocugen shares rose more than 760%. Ocugen said that it won't pursue Emergency Use Authorization (EUA) in the U.S. for its vaccine candidate -- known as Covaxin.